These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 9527686

  • 1. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
    Wandzel L.
    Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
    [Abstract] [Full Text] [Related]

  • 2. Predictors of drug treatment response in obsessive-compulsive disorder.
    Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G.
    J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
    [Abstract] [Full Text] [Related]

  • 3. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
    Rabinowitz I, Baruch Y, Barak Y.
    Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
    Sayyah M, Boostani H, Pakseresht S, Malayeri A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar 17; 34(2):362-5. PubMed ID: 20035818
    [Abstract] [Full Text] [Related]

  • 5. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD, Birkett M, Koran L, Genduso L.
    J Clin Psychiatry; 1994 Oct 17; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [Abstract] [Full Text] [Related]

  • 6. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ.
    J Am Acad Child Adolesc Psychiatry; 1992 Nov 17; 31(6):1062-9. PubMed ID: 1429406
    [Abstract] [Full Text] [Related]

  • 7. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG, Bouhassira M, Lancrenon S.
    Encephale; 2000 Nov 17; 26(6):73-83. PubMed ID: 11217541
    [Abstract] [Full Text] [Related]

  • 8. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions.
    Rosario-Campos MC, Miguel EC, Quatrano S, Chacon P, Ferrao Y, Findley D, Katsovich L, Scahill L, King RA, Woody SR, Tolin D, Hollander E, Kano Y, Leckman JF.
    Mol Psychiatry; 2006 May 17; 11(5):495-504. PubMed ID: 16432526
    [Abstract] [Full Text] [Related]

  • 9. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B, Bonnet-Perrin E.
    Encephale; 2001 May 17; 27(3):280-9. PubMed ID: 11488259
    [Abstract] [Full Text] [Related]

  • 10. [Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test].
    Harsányi A, Csigó K, Demeter G, Rajnai C, Németh A, Racsmány M.
    Psychiatr Hung; 2009 May 17; 24(1):18-59. PubMed ID: 19542567
    [Abstract] [Full Text] [Related]

  • 11. Course of obsessive-compulsive disorder during early postpartum period: a prospective analysis of 16 cases.
    Uguz F, Gezginc K, Zeytinci IE, Karatayli S, Askin R, Guler O, Sahin FK, Emul HM, Ozbulut O, Gecici O.
    Compr Psychiatry; 2007 May 17; 48(6):558-61. PubMed ID: 17954142
    [Abstract] [Full Text] [Related]

  • 12. Concurrent validity of the Yale-Brown Obsessive-Compulsive Scale-Symptom Checklist.
    Sulkowski ML, Storch EA, Geffken GR, Ricketts E, Murphy TK, Goodman WK.
    J Clin Psychol; 2008 Dec 17; 64(12):1338-51. PubMed ID: 18942133
    [Abstract] [Full Text] [Related]

  • 13. Convergent and discriminant validity of the Children's Yale-Brown Obsessive Compulsive Scale-Symptom Checklist.
    Gallant J, Storch EA, Merlo LJ, Ricketts ED, Geffken GR, Goodman WK, Murphy TK.
    J Anxiety Disord; 2008 Dec 17; 22(8):1369-76. PubMed ID: 18329843
    [Abstract] [Full Text] [Related]

  • 14. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH.
    Biol Psychiatry; 2005 Sep 01; 58(5):424-8. PubMed ID: 15993857
    [Abstract] [Full Text] [Related]

  • 15. Perceived parental rearing style in obsessive-compulsive disorder: relation to symptom dimensions.
    Alonso P, Menchón JM, Mataix-Cols D, Pifarré J, Urretavizcaya M, Crespo JM, Jiménez S, Vallejo G, Vallejo J.
    Psychiatry Res; 2004 Jul 15; 127(3):267-78. PubMed ID: 15296826
    [Abstract] [Full Text] [Related]

  • 16. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients.
    Levine R, Hoffman JS, Knepple ED, Kenin M.
    J Clin Psychopharmacol; 1989 Aug 15; 9(4):281-3. PubMed ID: 2504781
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.
    Greenberg WM, Benedict MM, Doerfer J, Perrin M, Panek L, Cleveland WL, Javitt DC.
    J Psychiatr Res; 2009 Mar 15; 43(6):664-70. PubMed ID: 19046587
    [Abstract] [Full Text] [Related]

  • 18. Sleep onset REM periods in obsessive compulsive disorder.
    Kluge M, Schüssler P, Dresler M, Yassouridis A, Steiger A.
    Psychiatry Res; 2007 Jul 30; 152(1):29-35. PubMed ID: 17316824
    [Abstract] [Full Text] [Related]

  • 19. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition.
    Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK.
    Psychol Assess; 2010 Jun 30; 22(2):223-32. PubMed ID: 20528050
    [Abstract] [Full Text] [Related]

  • 20. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report.
    Mukaddes NM, Abali O, Kaynak N.
    Psychiatry Clin Neurosci; 2003 Aug 30; 57(4):405-8. PubMed ID: 12839522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.